{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T06:04:42Z","timestamp":1774764282232,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cholangiocarcinoma (CCA) is a type of cancer with few effective systemic therapies. Elucidation of the molecular landscape of the disease from genomic studies based on next-generation sequencing (NGS) has contributed to the introduction of new targeted therapies. One of these treatments consists of a class of small molecules that target members of the fibroblast growth factor receptors (FGFRs) family of receptor tyrosine kinases. We report here on a patient with a cholangiocarcinoma bearing an FGFR2 mutation. The patient was treated with 2 different FGFR inhibitors, as the first caused ocular toxicity. She obtained clinical benefits from both. This case illustrates the efficacy of FGFR inhibitors on cholangiocarcinoma with specific point mutations.<\/jats:p>","DOI":"10.1093\/oncolo\/oyae294","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:49:27Z","timestamp":1746712167000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of 2 different fibroblast growth factor receptor-inhibitors in a patient with extrahepatic cholangiocarcinoma harboring an FGFR2 mutation: a case report"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4163-0630","authenticated-orcid":false,"given":"Ilianna","family":"Galli-Vareia","sequence":"first","affiliation":[{"name":"Department of Oncology, Centre Hospitalier Universitaire Vaudois , Lausanne 1011 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Szturz","sequence":"additional","affiliation":[{"name":"Department of Oncology, Centre Hospitalier Universitaire Vaudois , Lausanne 1011 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis A","family":"Voutsadakis","sequence":"additional","affiliation":[{"name":"Algoma District Cancer Program, Sault Area Hospital , Sault Ste Marie, ON P3E 2C6 ,","place":["Canada"]},{"name":"Division of Clinical Sciences, Section of Internal Medicine, Northern Ontario School of Medicine , Sudbury, ON P3E 2C6 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Villard","sequence":"additional","affiliation":[{"name":"Department of Radiology, Centre Hospitalier Universitaire Vaudois , Lausanne 1011 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Tsoumakidou","sequence":"additional","affiliation":[{"name":"Department of Radiology, Centre Hospitalier Universitaire Vaudois , Lausanne 1011 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mapi","family":"Fleury","sequence":"additional","affiliation":[{"name":"Department of Oncology, Centre Hospitalier Universitaire Vaudois , Lausanne 1011 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Oncology, Centre Hospitalier Universitaire Vaudois , Lausanne 1011 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Fasquelle","sequence":"additional","affiliation":[{"name":"Department of Pathology, Centre Hospitalier Universitaire Vaudois , Lausanne 1011 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastien","family":"Godat","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Centre Hospitalier Universitaire Vaudois , Lausanne 1011 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7189-3035","authenticated-orcid":false,"given":"Antonia","family":"Digklia","sequence":"additional","affiliation":[{"name":"Department of Oncology, Centre Hospitalier Universitaire Vaudois , Lausanne 1011 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"2025050809492450100_CIT0001","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/nejmoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"2025050809492450100_CIT0002","doi-asserted-by":"publisher","first-page":"e2019087","DOI":"10.4322\/acr.2019.087","article-title":"FOLFIRI as second-line treatment of metastatic biliary tract cancer patients","volume":"9","author":"Caparica","year":"2019","journal-title":"Autops Case Rep"},{"key":"2025050809492450100_CIT0003","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025050809492450100_CIT0004","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/jco.2019.37.15_suppl.4117","article-title":"Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations","volume":"37","author":"Park","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025050809492450100_CIT0005","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1158\/1078-0432.ccr-18-3334","article-title":"Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors","volume":"25","author":"Bahleda","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025050809492450100_CIT0006","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"2025050809492450100_CIT0007","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/s1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025050809492450100_CIT0008","doi-asserted-by":"publisher","first-page":"66","DOI":"10.11604\/pamj.2013.14.66.2178","article-title":"Apert syndrome","volume":"14","author":"Benmiloud","year":"2013","journal-title":"Pan Afr Med J"},{"key":"2025050809492450100_CIT0009","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fgene.2018.00181","article-title":"Apert Syndrome With FGFR2 758 C &gt; G mutation: a Chinese case report","volume":"9","author":"Li","year":"2018","journal-title":"Front Genet"},{"key":"2025050809492450100_CIT0010","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1093\/hmg\/ddv254","article-title":"Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin","volume":"24","author":"McDonell","year":"2015","journal-title":"Hum Mol Genet"},{"key":"2025050809492450100_CIT0011","doi-asserted-by":"publisher","first-page":"8713","DOI":"10.1073\/pnas.0803379105","article-title":"Drug-sensitive FGFR2 mutations in endometrial carcinoma","volume":"105","author":"Dutt","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025050809492450100_CIT0012","doi-asserted-by":"publisher","first-page":"7158","DOI":"10.1038\/sj.onc.1210529","article-title":"Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes","volume":"26","author":"Pollock","year":"2007","journal-title":"Oncogene"},{"key":"2025050809492450100_CIT0013","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"2025050809492450100_CIT0014","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"2025050809492450100_CIT0015","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1158\/2159-8290.CD-21-1547","article-title":"AACR Project GENIE: 100,000 Cases and Beyond","volume":"12","author":"Pugh","year":"2022","journal-title":"Cancer Discov"},{"key":"2025050809492450100_CIT0016","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"2025050809492450100_CIT0017","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"2025050809492450100_CIT0018","doi-asserted-by":"publisher","first-page":"17588359221125096","DOI":"10.1177\/17588359221125096","article-title":"A new promising oncogenic target (p.C382R) for treatment with pemigatinib in patients with cholangiocarcinoma","volume":"14","author":"Hempel","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"2025050809492450100_CIT0019","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025050809492450100_CIT0020","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II Study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025050809492450100_CIT0021","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"2025050809492450100_CIT0022","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1200\/JCO.2024.42.3_suppl.434","article-title":"Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: results from phase II clinical trial","volume":"42","author":"Milind","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025050809492450100_CIT0023","doi-asserted-by":"publisher","first-page":"e2317756121","DOI":"10.1073\/pnas.2317756121","article-title":"Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2","volume":"121","author":"Sch\u00f6nherr","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025050809492450100_CIT0024","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41698-021-00220-0","article-title":"Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma","volume":"5","author":"Bitzer","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2025050809492450100_CIT0025","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol Cancer Ther"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyae294\/63126917\/oyae294.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyae294\/63126917\/oyae294.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:49:28Z","timestamp":1746712168000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae294\/8126962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae294","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"oyae294"}}